Formulations of cross-linkable polymers capable of forming non-toxic and biocompatible hydrogels in situ containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM) nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.

Disclosed are once-daily formulations containing tetracyclines especially doxycycline. Such formulations are useful for instance for the treatment of collagenase destructive enzyme-dependent diseases such as periodontal disease and acne and acute and chronic inflammatory disease states such as rosacea and arthritis.

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer